PT-141 (Bremelanotide) + MK-677 (Ibutamoren) Stack: When to Pick One Over the Stack

What each compound actually is

Bremelanotide is a cyclic peptide of 7 amino acids and a melanocortin receptor agonist. It activates several receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R, and at therapeutic doses binding at MC1R and MC4R is most relevant. How it improves low sexual desire is unknown [1]. It is FDA-approved as Vyleesi, a 1.75 mg subcutaneous autoinjector, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [1][5].

'PT-141' products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [9][1].

MK-677 (ibutamoren mesylate) is not a peptide. It is an oral, non-peptide small molecule that stimulates growth hormone release by acting on the ghrelin receptor. Merck first synthesized it in 1995 and development was discontinued in 1999. It is not a component of any FDA-approved drug and has no USP or National Formulary monograph [3].

Is there any evidence for stacking them?

Bremelanotide and MK-677 act on different receptors [1][3]. The Vyleesi phase 3 trials and the MK-677 trials described on this page each tested one drug alone.

FDA's review of ibutamoren reports no formal drug-interaction studies [3]. The Vyleesi label's interaction section does not name ibutamoren. It says bremelanotide may slow gastric emptying and reduce absorption of oral medicines, that oral drugs dependent on threshold blood levels (for example antibiotics) should be avoided with it, and that it may significantly decrease levels of oral naltrexone. In the label's clinical pharmacology studies only naltrexone and indomethacin were meaningfully affected [1].

When PT-141 alone is the right pick

When the goal is sexual desire in a premenopausal woman with acquired, generalized HSDD, bremelanotide is the only one of the two with an approved indication, a label dose and phase 3 data [1][2].

The label dose is 1.75 mg subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The Vyleesi label limits use to one dose in 24 hours and does not recommend more than eight doses per month, and it says to stop after 8 weeks if there is no improvement in symptoms; how long a single dose works is unknown [1].

Results were statistically significant. On the FSFI desire domain (score range 1.2 to 6.0), mean change from baseline was 0.5 points versus 0.2 on placebo in Study 1 and 0.6 versus 0.2 in Study 2 [1]. The integrated desire improvement across the two trials was 0.35 points (P<0.001) [2]. There was no significant difference in the number of satisfying sexual events [2].

In the pooled phase 3 trials (627 women on Vyleesi, 620 on placebo), nausea occurred in 40.0% versus 1.3%, flushing in 20.3% versus 0.3%, and headache in 11.3% versus 1.9%. Discontinuation because of adverse reactions was 18% versus 2% [1].

The label does not indicate bremelanotide for men, for postmenopausal women, or to enhance sexual performance [1].

When the goal is body composition or IGF-1 instead

MK-677 is not a close substitute here. It has no approved dose — adult trials used 2 mg to 50 mg a day, most often 25 mg [3]. It raised IGF-1 and fat-free mass in some trials, but a study in healthy older adults found no improvement in strength or function, and studies in hip-fracture patients found little functional benefit [6][8][7].

In a trial of 65 healthy adults aged 60 to 81, participants received MK-677 at 25 mg daily or placebo for 12 months: fat-free mass rose 1.1 kg versus a 0.5 kg fall on placebo, and body weight rose 2.7 kg versus 0.8 kg. Strength and function did not improve. Fasting glucose rose about 5 mg/dL and insulin sensitivity fell [6].

In 123 hip-fracture patients aged 60 and older, the trial was stopped early for a safety signal of congestive heart failure — 4 patients (6.5%) on MK-677 versus 1 (1.7%) on placebo, per FDA's summary — with higher blood pressure, more serious adverse events and larger rises in blood glucose and HbA1c than placebo [8][3].

In 563 patients with mild to moderate Alzheimer's disease, IGF-1 rose 72.9% over 12 months and disease progression did not change. Drug-related adverse events were 35.5% versus 23.9%, blood glucose increases 15.4% versus 4.6%, and HbA1c increases 11.1% versus 1.4% [10].

In a separate trial of 24 obese men, 12 received MK-677 at 25 mg daily and 12 received placebo for 8 weeks: IGF-1 rose about 40% and fat-free mass increased, but total and visceral fat did not change and an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks [11].

Regulatory status matters for anyone actually choosing between the two. FDA lists ibutamoren mesylate among bulk substances that raise significant safety risks for compounding, citing 'the potential for congestive heart failure in certain patients', and a hip-fracture trial 'terminated early due to a potential safety signal of congestive heart failure' [4][8]. FDA's Pharmacy Compounding Advisory Committee voted 1 yes, 13 no against adding it to the list of bulk substances pharmacies may compound [12]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [13]. WADA names ibutamoren in S2.2.4 and prohibits it at all times [14]. In a December 12, 2025 warning letter, FDA stated that ibutamoren is excluded from the dietary supplement definition and that products marketed with drug claims for it are unapproved new drugs [15].

What each one does to blood pressure and glucose

The Vyleesi label describes a transient increase in blood pressure and decrease in heart rate after each dose: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute and values usually back to baseline within 12 hours. No additive effect was seen with once-daily dosing for up to 16 days [1]. In a separate ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high risk for cardiovascular disease [1].

On the MK-677 side, glucose is the consistent finding. Fasting glucose rose about 5 mg/dL over a year in healthy older adults [6], blood glucose increases were reported in 15.4% versus 4.6% of patients in the Alzheimer's trial [10], and the 8-week obesity study found impaired glucose handling [11]. In the hip-fracture study, systolic blood pressure rose 11.9 to 16.4 mmHg versus 2.3 to -2.3 mmHg on placebo [8][3]. In a separate 6-month hip-fracture trial of 161 patients, edema or fluid overload was recorded in 16 patients on MK-0677 versus 10 on placebo, thrombosis in 4 versus 0, and glucose rose 8.0 mg/dL versus a 1.6 mg/dL fall [7][3].

A short decision summary

• Desire is the only goal. Bremelanotide is the one with a label dose, an approved population and phase 3 data [1][2].
• Body composition or IGF-1 is the only goal. In healthy older adults, the fat-free-mass gain did not improve strength or function; a hip-fracture trial found improved gait speed but no improvement in most other functional measures, and glucose rose in several trials [6][8][10][11].
• Both goals are present. The two drugs act on different receptors and have not been tested together; MK-677's regulatory status is described above [1][3].
• Known cardiovascular disease or uncontrolled hypertension. The Vyleesi label contraindicates bremelanotide in both [1].